Beyond the transplant list: the pediatric cardiomyopathy pipeline finally has momentum

Dilated cardiomyopathy (DCM) is the most common form of cardiomyopathy in children and the leading reason kids end up on a heart transplant list. For decades, when medical management failed, transplant was often the only option left. That’s starting to change, as pharmaceutical companies and academic centers push into the underlying mechanisms of pediatric heart muscle disease rather than just managing its symptoms.

The gap this pipeline is trying to close

Hypertrophic cardiomyopathy (HCM) is less common than DCM in children but carries real risk, including sudden cardiac death in young people. Right now, there are effectively no approved pharmacologic therapies for pediatric HCM — treatment is extrapolated from adult practice, often empirically and imperfectly. For DCM patients who progress to end-stage heart failure, transplant remains curative but constrained: donor hearts for children are scarce, and the procedure comes with lifelong immunosuppression.

Cardiac myosin inhibitors move into adolescents

The most concrete near-term progress comes from cardiac myosin inhibitors — mavacamten (Camzyos, Bristol Myers Squibb) and aficamten (Cytokinetics) — both now in pediatric development for symptomatic obstructive HCM.

Mavacamten reached a real milestone: Bristol Myers Squibb presented Phase 3 SCOUT-HCM results at the American College of Cardiology’s ACC.26 meeting in March 2026, the first study of a cardiac myosin inhibitor in adolescents (ages 12 to under 18), with results published simultaneously in the New England Journal of Medicine. The trial met its primary endpoint — a placebo-adjusted least-squares mean reduction in Valsalva LVOT gradient of −48.0 mmHg at week 28 (P < 0.0001) — with a safety profile in adolescents consistent with the adult data and no new signals, according to Bristol Myers Squibb’s own release and corroborating coverage from the ACC and HCPLive. Joseph Rossano, the trial’s principal investigator and chief of cardiology at Children’s Hospital of Philadelphia, called it a significant advance for a population that previously had no approved options.

Aficamten’s CEDAR-HCM trial — targeting the same hypercontractility mechanism — is enrolling roughly 55 adolescents with plans to expand into children aged 6 to under 12, according to the original trial description; started in May 2024, with completion projected for 2030.

Gene therapy: earlier stage, and worth reading the fine print on

Tenaya Therapeutics is developing TN-201, an AAV9 gene therapy for MYBPC3-associated HCM. Its interim MyPEAK-1 data — presented in June 2026, showing improvements in cardiac remodeling and symptom burden across six evaluable patients, with benefits sustained out to two years in the earliest cohort — comes from an adult trial population, according to Tenaya Therapeutics’ press materials and June 2026 earnings call. TN-201’s pediatric use is a separate, earlier-stage track: it has PRIME designation from the European Medicines Agency and has been accepted into the FDA’s Rare Disease Evidence Principles Process, but pediatric efficacy data isn’t yet in hand.

Elsewhere, Affinia Therapeutics presented new AAV data for BAG3-associated DCM at the ASGCT 2026 meeting, and preclinical Perm1 gene therapy work has shown early promise against PRDM16-associated cardiomyopathy, according to the original.

Repurposing existing drugs

Empagliflozin, an SGLT2 inhibitor already established in adult heart failure, is being tested in a Phase 2a trial for Duchenne muscular dystrophy-associated cardiomyopathy, enrolling patients aged 6 to 18 — a rationale worth taking seriously given heart failure is now the leading cause of death in DMD. The VALOR study (an investigational drug in pediatric heart failure) and research into ARNI therapy in Egyptian children with DCM are both described in the source material as ongoing; according to the original review, pending confirmation from ClinicalTrials.gov, without visible sponsor, phase, or enrollment details for either.

Stem cells and surgery

Longeveron has FDA IND approval for laromestrocel, a stem cell therapy for pediatric DCM, allowing the program to move directly into a Phase 2 pivotal trial, according to the company. A separate 2026 case report described the first use of allogeneic Wharton’s Jelly-derived mesenchymal stromal cells via intracoronary transplantation in pediatric DCM patients — a single case report, not a controlled trial, so its results shouldn’t be read as more than hypothesis-generating.

On the surgical side, reversible pulmonary artery banding has resurfaced as a strategy to promote left ventricular recovery in pediatric DCM. A 2026 systematic review found it was associated with significant reverse remodeling and favorable native-heart survival, per the review cited in the source.

The bottom line

Pediatric trials face real structural limits — small populations, disease heterogeneity, thin pediatric-specific data. But across five different modalities, the pipeline behind pediatric cardiomyopathy is thicker than it’s been in years. For families facing this diagnosis, that’s the first real chance in a long time that transplant might not be the only road forward.